Tredje AP fonden boosted its stake in Pfizer Inc. (NYSE:PFE) by 1.2% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 733,730 shares of the biopharmaceutical company’s stock after acquiring an additional 8,492 shares during the quarter. Pfizer accounts for approximately 0.9% of Tredje AP fonden’s portfolio, making the stock its 9th largest position. Tredje AP fonden’s holdings in Pfizer were worth $26,194,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors also recently modified their holdings of PFE. Vanguard Group Inc. raised its holdings in shares of Pfizer by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after acquiring an additional 9,239,499 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Pfizer by 4.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 59,844,024 shares of the biopharmaceutical company’s stock valued at $2,136,189,000 after buying an additional 2,502,659 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of Pfizer by 0.9% during the 2nd quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock valued at $1,550,754,000 after buying an additional 389,629 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Pfizer by 4.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock valued at $1,487,617,000 after buying an additional 2,028,313 shares in the last quarter. Finally, Fisher Asset Management LLC raised its holdings in shares of Pfizer by 3.2% during the 3rd quarter. Fisher Asset Management LLC now owns 35,120,799 shares of the biopharmaceutical company’s stock valued at $1,253,813,000 after buying an additional 1,085,437 shares in the last quarter. Institutional investors and hedge funds own 70.12% of the company’s stock.
PFE has been the topic of a number of research reports. UBS Group set a $40.00 price objective on Pfizer and gave the company a “buy” rating in a report on Wednesday, December 6th. Sanford C. Bernstein set a $43.00 price objective on Pfizer and gave the company a “buy” rating in a report on Tuesday, January 30th. BMO Capital Markets reissued a “buy” rating and set a $39.00 price objective on shares of Pfizer in a report on Friday, November 10th. Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price objective on the stock in a report on Wednesday, January 17th. Finally, Vetr raised Pfizer from a “hold” rating to a “buy” rating and set a $38.82 price objective on the stock in a report on Thursday, November 23rd. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $39.45.
In other news, EVP Rady A. Johnson sold 8,000 shares of Pfizer stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the sale, the executive vice president now directly owns 46,963 shares in the company, valued at approximately $1,740,918.41. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Alexander R. Mackenzie sold 6,750 shares of Pfizer stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the sale, the insider now owns 103,458 shares in the company, valued at $3,827,946. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by company insiders.
Pfizer Inc. (NYSE:PFE) opened at $36.26 on Monday. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56. Pfizer Inc. has a 1 year low of $31.67 and a 1 year high of $39.43. The stock has a market capitalization of $216,135.23, a P/E ratio of 13.68, a P/E/G ratio of 2.05 and a beta of 0.94.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The business had revenue of $13.70 billion for the quarter, compared to analyst estimates of $13.67 billion. During the same period last year, the company earned $0.47 EPS. Pfizer’s revenue for the quarter was up .6% compared to the same quarter last year. analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be given a $0.34 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.75%. The ex-dividend date of this dividend is Thursday, February 1st. Pfizer’s dividend payout ratio (DPR) is currently 38.75%.
Pfizer announced that its Board of Directors has authorized a share buyback program on Monday, December 18th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board believes its shares are undervalued.
TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/19/pfizer-inc-pfe-shares-bought-by-tredje-ap-fonden.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.